Jin Medical International Ltd. (ZJYL) reported financial results for the first half of fiscal year 2026. Half-year financial results provide performance data that can shift investor views on valuation and operations.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 16.70 | 26.76 | 29.63 | 30.10 |
| Receivables | 8.47 | 8.56 | 5.91 | 5.53 |
| Inventory | 5.05 | 5.17 | 4.92 | 5.75 |
| Other | — | — | — | 0.64 |
| 31.12 | 42.82 | 44.14 | 44.56 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 3.39 | 3.01 | 3.26 | 2.60 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 8.92 | 17.15 | 23.80 | 22.82 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
20.69
|
| ’24 | — | — | — | — |
23.50
|
| ’23 | 10.25 | — | — | — |
19.82
|
| ’22 | — | — | — | — |
19.19
|
| ’21 | — | — | — | — |
19.19
|
| ’21 | — | — | — | — |
20.76
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.93) | — | — | — |
—
|
| ’25 | 2.56 | — | 2.90 | — |
2.90
|
| ’24 | 0.05 | — | (1.21) | — |
(1.21)
|
| ’23 | 2.74 | — | 3.11 | — |
3.11
|
| ’22 | — | — | 1.58 | — |
1.58
|
| ’21 | — | — | — | — |
5.84
|
| ’20 | — | — | — | — |
2.50
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (2.72) | — | — | — |
—
|
| ’25 | 0.51 | — | (3.72) | — |
(3.73)
|
| ’24 | (1.01) | — | (1.35) | — |
(2.33)
|
| ’23 | 2.74 | — | 3.00 | — |
3.00
|
| ’22 | — | — | 1.54 | — |
1.54
|
| ’21 | — | — | — | — |
5.84
|
| ’20 | — | — | — | — |
2.50
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
0.20
|
| ’24 | — | — | — | — |
0.40
|
| ’23 | 0.23 | — | — | — |
0.40
|
| ’22 | — | — | — | — |
0.34
|
| ’21 | — | — | — | — |
0.33
|
| ’20 | — | — | — | — |
0.28
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 4.84 | 14.02 | 3.62 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | 509.87 | 332.00 | 23.80 | — | — | — |
High Price
|
| — | — | — | — | — | — | 258 | 245 | 269 | 273 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.08 | 0.09 | 0.08 | — | — | — |
Revenue/Emp
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.19 | 19.82 | 23.50 | 20.69 | — | — | — |
Revenue
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 32.30% | 34.23% | 40.43% | 29.22% | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.74 | 3.22 | 4.18 | 1.60 | — | — | — |
EBT
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.29% | 16.25% | 17.80% | 7.71% | — | — | — |
EBT Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.71 | 2.88 | 3.42 | 1.38 | — | — | — |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.36 | 0.23 | 0.24 | 0.24 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.84 | 2.73 | 3.00 | 2.64 | — | — | — |
Revenue/Sh
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 0.34 | 0.40 | 0.40 | 0.20 | — | — | — |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.23 | 0.43 | (0.15) | 0.37 | — | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | (0.01) | (0.01) | (0.14) | (0.85) | — | — | — |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.23 | 0.41 | (0.30) | (0.48) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.26 | 3.30 | 3.65 | 3.78 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.75 | 7.26 | 7.82 | 7.83 | — | — | — |
Shares
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
PE Ratio
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
PS Ratio
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 7.55 | 14.60 | 2.96 | — | — | — |
PB Ratio
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 90.65 | (12.92) | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.58 | 3.11 | (1.21) | 2.90 | — | — | — |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.04) | (0.10) | (1.12) | (6.63) | — | — | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.54 | 3.00 | (2.33) | (3.73) | — | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.20 | 22.19 | 25.66 | 20.35 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.07) | (16.70) | (26.76) | (29.63) | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 15.24 | 23.98 | 28.55 | 29.57 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.93% | 17.49% | 9.34% | 2.40% | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 16.30% | 24.61% | 126.69% | 0.00% | — | — | — |
ROIC
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.26% | 14.68% | 14.00% | 4.10% | — | — | — |
ROE
|
Jin Medical International Ltd. (ZJYL), a niche Chinese provider of disposable medical supplies like infusion sets and syringes, has endured a decade of volatility in the competitive medtech sector, marked by steady but modest revenue in the $16-24 million range since 2019, aggressive share dilution (shares exploding 1,856% to 156.5 million), and wild stock swings—now trading 92% below its 2023 peak. While demand from hospitals drove rebounds post-COVID disruptions (e.g., +18.6% revenue to $23.5 million in 2024 with improving efficiency), profitability remains erratic, with EBT margins peaking at 17.8% before a forecasted 2025 plunge amid rising raw material costs and hospital pricing pressures.
Dilution has ravaged per-share metrics—revenue per share cratering to $0.13 and EPS stuck at $0.02—despite balance sheet resilience, including 176% equity growth to $29.6 million and ample working capital. Cash flows show volatility, with 2025 capex surging 489% for potential upgrades, but net debt worsening to -$29.6 million signals risks. Absent insider buying or analyst targets, the stock’s deep discount hints at undervaluation in China’s aging population-driven healthcare boom, yet bearish forecasts (12% revenue drop, 60% net income cut) underscore high-risk speculation.
For contrarian investors, ZJYL offers a intriguing bet on medtech localization tailwinds and margin recovery potential (bull case: 50-100% upside if dilution halts), but dilution scars, sentiment apathy, and macro headwinds demand caution—watch Q1 2026 earnings for capex payoff and insider signals.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.